Tech Company Financing Transactions
KalVista Pharmaceuticals Funding Round
KalVista Pharmaceuticals, based in Cambridge, secured $33 million from RA Capital, Longwood Fund and Novo Ventures.
Transaction Overview
Company Name
Announced On
7/23/2015
Transaction Type
Venture Equity
Amount
$33,000,000
Round
Series B
Investors
Proceeds Purpose
KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
55 Cambridge Pkwy. 901E
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
KalVista is a research-led pharmaceutical company focused on the discovery, development and commercialization of small molecule serine protease inhibitors as new treatments for diseases with significant unmet need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andrew Crockett
Chief Financial Officer
Benjamin Palleiko
Chief Medical Officer
Andreas Maetzel
Chief Scientific Officer
Edward Feener
VP - Bus. Development
Michael Smith
VP - Bus. Development
Christopher Yea
Browse more venture capital transactions:
Prev: 7/23/2015: Zimplistic venture capital transaction
Next: 7/23/2015: BlueCava venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs